April 6, 2023​

Welcome to hubXchange’s East Coast Genomics in Precision Oncology 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in genomics-led oncology precision medicine strategies.

Discussion topics will cover Cancer Genomics, Translational Bioinformatics, Data Quality & Access and Genomics Informed Clinical Decisions.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Venue Details: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801

Cancer Genomics

Titles and Bullets
8:00 – 8:30am
8:30 – 9:00am

Opening Address & Keynote Presentation

9:05 – 10:05am

How to design drug combinations with Immuno-oncology treatment

  • How to identify resistance mechanisms to immune checkpoint therapy ?
  • How to potentiate the existing immune therapy ?
  • How to find a combination therapy aiming at a different cell type ?
  • How to design a standard chemo or targeted therapy in combination ?

Senior Research Scientist, Sanofi

With a dual background in pharmaceutical sciences and cancer bioinformatics, Mike Yang use machine learning to elucidate disease mechanisms, with the ultimate goal of new drug discovery and combination. Mike was initially trained as a pharmacist at the University of Paris-Sud. Then as a PhD student at Heidelberg University, he developed computational methods for drug synergy prediction and mechanistic exploration from large scale cancer drug screening datasets. At Stanford, he built a computational framework for drug discovery in immuno-oncology. At PrognomIQ, he worked on multi-omics cancer early detection from liquid biopsy. Mike is currently working as a senior scientist in oncology bioinformatics at Sanofi.

Mike Yang
10:10 – 10:40am
1-2-1 Meetings/Networking Break
10:40 – 11:10am
1-2-1 Meetings / Networking Break
11:10 – 11:20am
Morning Refreshments
12:20 – 1:20pm
Networking Lunch
1:25 – 2:25pm

The state of progress of precision medicine in immuno-oncology

  • With more than 70 immunotherapy drugs in the clinical pipeline how are we balancing our understanding of the tumor specific immune landscape and the feasibility of trying to address all our questions clinically?
  • What are the features of the successful patient enrichment biomarkers in immune oncology and what can we learn from them?
  • Beyond a mouse! How do we develop better model systems to reflect the complexity of the human immune system and cancer?
  • What is the role of the ‘surrogate biomarker’ that we could consider adopting in immune therapy
  • How do we consider the ‘immune therapy combination’ and the need to establish biomarkers in drug development

Chief Scientific Officer, Corbus Pharmaceuticals

A molecular and cellular biologist by training, Rachael is a deeply experienced drug developer that has been employed by various bio/pharma organizations including Amgen, Millennium/Takeda, and most recently Corbus Pharmaceuticals, where she currently serves as the Chief Scientific Officer. There Rachael is focused on attempting to wrangle the cytokine TGFb a known immunosuppressive growth factor in many cancers. Rachael’s 20+ years of drug development experience has been focused on advancing therapeutic programs across various mechanisms of action and modalities in immunology /oncology. Rachael brings significant pharmaceutical research and development experience, having focused on translating basic research concepts into effective clinical development strategies for many years. Previously at Takeda Rachael led the US Medical Affairs organization in Oncology, and also led the late-stage clinical development portfolio for solid tumors, where she successfully led the teams responsible for the front line approval of ALUNBRIG and established development strategies for programs like mobocertinib and sapanistertib. Rachael is an Australian, but currently resides in Boston, MA. She completed her BSc at the Australian National University and her PhD at the University of Western Australia /Institute for Child Health Research in Perth, WA.

Rachael Brake
2:30 – 3:00pm
1-2-1 Meetings / Networking Break
3:00 – 3:30pm
1-2-1 Meetings / Networking Break
3:30 – 3:45pm
Afternoon Refreshments

3:45 – 4:45pm

ctDNA for cancer monitoring and MRD

  • Limited predictive markers exist for PD1/PDL1 inhibitors- can we improve measurements?
  • How can we define novel biomarkers for PD1/PDL1 inhibitors?
  • How can we identify predictive biomarkers for novel IO agents?

Vice President, Translational Science, Oncology, AstraZeneca

Dr. J. Carl Barrett is Vice President & Global Head of Translational Medicine Oncology R&D at AstraZeneca. He is responsible for development and execution of biomarker strategies and translational sciences efforts to support compound development from research through early and full development in oncology.

Previously, Dr. Barrett was the founding Director of the NCI Center for Cancer Research (CCR), the NCI intramural center for translation medicine. He was also Scientific Director at the National Institute of Environmental Health Sciences where he focused on integrating new approaches to toxicogenomics, molecular toxicology, and the Environmental Genome Project.

J.Carl Barrett
4:45 – 5:45pm
Evening Drinks Reception


Genomics in Precision Oncology | East Coast 2023